CHAPEL HILL, N.C. — On Wednesday, the nation’s coronavirus task force announced positive clinical trial results for remdesivir, a treatment that originated in the labs at the University of North Carolina at Chapel Hill.
The treatment diminished the time to recover from COVID-19.
Animal testing at UNC Gillings School of Public Health set the stage for clinical trials to begin this spring as the virus spread across the globe, the university said in a news release.
“This is a game changer for the treatment of patients with COVID-19 and provides hope to many infected,” said Ralph Baric, an epidemiologist in the UNC Gillings School of Public Health that led lab testing of the broad-spectrum antiviral drug.
Six years ago, the UNC lab partnered with the biopharmaceutical company Gilead Sciences Inc. Their goal was testing the company’s antiviral drugs to curb emerging viral diseases, according to Tim Sheahan, a virologist in Baric’s lab.
“The intravenous drug remdesivir could provide relief during a global pandemic that has taken the lives of nearly 60,000 Americans and sickened more than 1 million in the United States,” the release said.
